CN103372174A - Compound traditional Chinese medicine for treating depression - Google Patents
Compound traditional Chinese medicine for treating depression Download PDFInfo
- Publication number
- CN103372174A CN103372174A CN201210126887XA CN201210126887A CN103372174A CN 103372174 A CN103372174 A CN 103372174A CN 201210126887X A CN201210126887X A CN 201210126887XA CN 201210126887 A CN201210126887 A CN 201210126887A CN 103372174 A CN103372174 A CN 103372174A
- Authority
- CN
- China
- Prior art keywords
- depression
- parts
- chinese medicine
- treatment
- herbal mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a compound traditional Chinese medicine for treating depression. The compound traditional Chinese medicine taking Chinese herbaceous peony, radix bupleurim, turmeric, hyperforin perforatum, purple perilla, rhizoma anemarrhenae and long pepper as raw materials is extracted and separated by 0-75% ethanol and prepared as medically acceptable oral preparations such as troches, capsules (soft or hard capsules) and particles. The drafted major functions of the compound traditional Chinese medicine are soothing liver-qi stagnation and dispersing blood stasis and dredging collateral, and the compound traditional Chinese medicine is used for treating mild-to-moderate depression. The pharmacological researches show that the pharmaceutical composition can remarkably enhance open field activity of chronic stress depression mode mice and increase the consumption of sweet water; antagonizes akinesia and hypothermia of chronic stress depression mode mice induced by reserpine, so that the number of autonomic activities of despair animal mode induced by tail suspension and forced swimming and tail suspension and swimming immobility time are increased. The compound traditional Chinese medicine disclosed by the invention with the functions of soothing liver-qi stagnation is an effective special medicine for treating depression.
Description
Technical field
The invention belongs to medical technical field, relate to a kind of medicine of Cure of depression, is the herbal mixture that comprises Radix Paeoniae, the Rhizoma Anemarrhenae, Rhizoma Curcumae Longae, Herba Hyperici perforati, Radix Bupleuri, Folium Perillae, Fructus Piperis Longi specifically.
Background technology
Depression is a kind of common emotion and mental disorder disease, and along with the quickening of social life rhythm, depression has become the disease occurred frequently of society.World Health Organization's statistics in 2005, the prevalence of various depressions accounts for 11% of population in the world.Show that according to China's Epidemiological study in 2003 China has 3,600 ten thousand patients with depression at least, wherein only has 5% severe patient to accept associated treatment.Many major depression patients are arranged because in time not carrying out the regular treatment committed suicide.According to death toll in 2003 according to one's analysis, China has 28.7 ten thousand population committed suicides every year at least.Suicide is the 5th cause of the death in the population of China, is first cause of the death of 15～34 years old crowd.Therefore, the drug research of reinforcement Cure of depression has important society and economic implications.
Treatment for depression, at present doctor trained in Western medicine adopts 5-hydroxy tryptamine reuptake depressant, monoamine oxidase inhibitor, phenyl piperazines, 5-hydroxy tryptamine-norepinephrine reuptake inhibitor, aminoketones, tricyclic antidepressants, Fourth Ring sends the 7 class antidepressants such as piperazine azatropylidene class more, but synthetic antidepressants exist mostly that the antidepressant spectrum is narrow, toxic and side effects large, the medicine valency high and the defective such as easy recurrence.Therefore, both at home and abroad aspect exploitation, more and more pay attention to traditional drugs (more than 2,000 year historical Chinese herbal medicine particularly arranged) in the development of antidepressants, even to develop American-European countries that synthetic drug is good at also the main force medicine of some true medicable traditional drugss as Cure of depression.
Depressed card belongs to the melancholia category of the traditional Chinese medical science, and disease is complicated and changeable, how to cause owing to feelings will is upset.Chinese medicine compound has the advantages that composition is many, the effect link is many, target spot is many, and multicomponent synergism, has remedied the low characteristics of active constituent content, has reduced side effect.Therefore, development antidepressant good effect, side effect little, be fit to long-term taking and safe and reliable Chinese medicine composition has become current study hotspot.The present invention has the characteristics of dispersing the stagnated live-QI to relieve the stagnation of QI, disperse blood stasis and dredge collateral, is mainly used in light, moderate depressive patients.
Summary of the invention
The purpose of this invention is to provide a kind of Chinese medicine composition and preparation thereof that is used for the treatment of depression.
The pharmaceutical composition of Cure of depression of the present invention comprises the raw material of Chinese medicine of following weight portion proportioning: 0.8～3 part of Radix Paeoniae, 0.3～2 part in Rhizoma Curcumae Longae, 0.2～1 part of Herba Hyperici perforati, 0.5～2 part of Radix Bupleuri, 0.5～2 part of Folium Perillae.
Preferably, the raw material of Chinese medicine that comprises following weight portion proportioning: 0.8～3 part of Radix Paeoniae, 0.3～2 part in Rhizoma Curcumae Longae, 0.2～1 part of Herba Hyperici perforati, 0.5～2 part of Radix Bupleuri, 0.5～2 part of Folium Perillae, 0～3 part of the Rhizoma Anemarrhenae.
And then more preferably, comprise the raw material of Chinese medicine of following weight portion proportioning: 0.8～3 part of Radix Paeoniae, 0.3～2 part in Rhizoma Curcumae Longae, 0.2～1 part of Herba Hyperici perforati, 0.5～2 part of Radix Bupleuri, 0.5～2 part of Folium Perillae, 0～3 part of the Rhizoma Anemarrhenae, 0～1 part of Fructus Piperis Longi.
Aforementioned pharmaceutical compositions is taken after can decocting, also can water or ethanol extraction after make Chinese patent medicine and take.
The preparation method of drug combination preparation of the present invention can adopt the conventional method of pharmaceutical field, uses conventional pharmaceutic adjuvant to carry out.For example adopt conventional method that carrier or adjuvant commonly used on extract and any one or more than one pharmaceutics are mixed, then make various peroral dosage forms.Described carrier such as excipient, filler, diluent, lubricant, wetting agent, disintegrating agent, surfactant, antiseptic, sweeting agent, aromatic etc.Particularly, described carrier such as starch, dextrin, lactose, microcrystalline Cellulose, hydroxypropyl methylcellulose, Polyethylene Glycol, magnesium stearate, micropowder silica gel, glucose, mannitol, xylitol, glycine etc.
As required, pharmaceutical composition of the present invention can be made into the preparation that is suitable for oral medication, can be following arbitrary dosage form: tablet, capsule, granule, pill, oral liquid etc., preferred soft capsule, dispersible tablet, oral cavity disintegration tablet, drop pill.
Another object of the present invention is that a kind of preferred preparation method also is provided, and the preparation method of the Chinese medicine composition of Cure of depression or depressive state namely is provided, and the method comprises the steps:
In raw material of Chinese medicine, add 0～70% ethanol, extract 2～3 times, add 4～12 times of amount solvents at every turn; The each extraction 1～2 hour, extracting solution filters, and reclaims solvent and concentrated, and drying is pulverized, as the raw material of composite preparation.
Another purpose of the present invention provides this pharmaceutical composition in the application of the aspects such as Cure of depression.
The present invention's flavour of a drug of writing out a prescription share, and have the function of dispersing the stagnated live-QI to relieve the stagnation of QI, disperse blood stasis and dredge collateral.The pharmacological research of the compositions that the party is extracted shows that said composition all has the anti-inhibitory action of specificity to multiple depression model.
The specific embodiment
For the present invention is further described in detail, provide specific embodiment, but only the present invention is illustrated in conduct, rather than in order to limit the scope of the invention.
The granule dosage form of embodiment 1 pharmaceutical composition of the present invention
Adopt conventional preparation granule method, get 3 parts of Radix Paeoniaes, 2.4 parts of the Rhizoma Anemarrhenaes, 1.2 parts in Rhizoma Curcumae Longae, 0.9 part of Herba Hyperici perforati, 1.8 parts of Radix Bupleuri, 1.8 parts of Folium Perillaes, 0.3 part of Fructus Piperis Longi, soak after 0.5 hour and extract 2 times, amount of water is respectively 10 times, 8 times, extracts 2 hours for the first time, extracts 1.5 hours for the second time, filter, merging filtrate, concentrated, dry, add right amount of auxiliary materials, mixing after pulverizing, granulate, sieve, drying makes the drug combination preparation of granule dosage form.
The tablet form of embodiment 2 pharmaceutical compositions of the present invention
Adopt the conventional method for preparing tablet, get 0.8 part of Radix Paeoniae, 1 part of the Rhizoma Anemarrhenae, 0.3 part in Rhizoma Curcumae Longae, 0.2 part of Herba Hyperici perforati, 0.5 part of Radix Bupleuri, 0.5 part of Folium Perillae, 0.5 part of Fructus Piperis Longi, soak after 0.5 hour and extract 2 times, amount of water is respectively 6 times, 4 times, extracted 2 hours for the first time, extracted 1 hour for the second time, filter merging filtrate, concentrated, dry, add right amount of auxiliary materials after pulverizing, mixing is granulated, and sieves, dry, through further tabletting, drying namely makes the drug combination preparation of Tabules with the granule that makes.
The capsule formulation of embodiment 3 pharmaceutical compositions of the present invention
Adopt the conventional method for preparing capsule, get 2 parts of Radix Paeoniaes, 1.5 parts of the Rhizoma Anemarrhenaes, 1 part in Rhizoma Curcumae Longae, 0.6 part of Herba Hyperici perforati, 1.5 parts of Radix Bupleuri, 1.5 parts of Folium Perillaes, 1 part of Fructus Piperis Longi, adding 60% soak with ethanol extracted 2 times after 0.5 hour, amount of water is respectively 7 times, 5 times, extracted 2 hours for the first time, extracted 1 hour for the second time, filter merging filtrate, concentrated, dry, add right amount of auxiliary materials after pulverizing, mixing is granulated, and sieves, dry, the granule that makes is incapsulated shell, make capsule, namely make the drug combination preparation of capsule formulation.
The drops of embodiment 4 present compositions
Preparation: the technique that adopts conventional preparation drop pill, get 1.5 parts of Radix Paeoniaes, 1.5 parts of the Rhizoma Anemarrhenaes, 0.8 part in Rhizoma Curcumae Longae, 0.5 part of Herba Hyperici perforati, 1 part of Radix Bupleuri, 1 part of Folium Perillae, 0.8 part of Fructus Piperis Longi, adding 50% soak with ethanol extracted 2 times after 0.5 hour, amount of water is respectively 6 times, 4 times, extracts 2 hours for the first time, extracts 1 hour for the second time, filter, merging filtrate, concentrated, dry, add right amount of auxiliary materials after pulverizing, make the drop pill of this pharmaceutical composition.
The soft capsule dosage form of embodiment 5 present compositions
Preparation: adopt the technique of conventional preparation soft capsule, get 1.2 parts of Radix Paeoniaes, 1.5 parts of the Rhizoma Anemarrhenaes, 1 part in Rhizoma Curcumae Longae, 0.3 part of Herba Hyperici perforati, 0.7 part of Radix Bupleuri, 0.8 part of Folium Perillae, 0.6 part of Fructus Piperis Longi, add 40% soak with ethanol and extract 2 times after 0.5 hour, amount of water is respectively 7 times, 5 times, extracted 2 hours for the first time, extracted 1 hour for the second time, filter, merging filtrate, concentrated, dry, add right amount of auxiliary materials after pulverizing, mixing is made capsule casing material with gelatin, be pressed into soft capsule, make the soft capsule of this pharmaceutical composition.
The micropill dosage form of embodiment 6 present compositions
Preparation: the technique that adopts conventional preparation micropill, get 1 part of Radix Paeoniae, 1 part of the Rhizoma Anemarrhenae, 0.6 part in Rhizoma Curcumae Longae, 0.3 part of Herba Hyperici perforati, 0.9 part of Radix Bupleuri, 0.7 part of Folium Perillae, 0.4 part of Fructus Piperis Longi, adding 30% soak with ethanol extracted 2 times after 0.5 hour, amount of water is respectively 6 times, 4 times, extracts 2 hours for the first time, extracts 1 hour for the second time, filter, merging filtrate, concentrated, dry, add right amount of auxiliary materials after pulverizing, make the micropill of this pharmaceutical composition.
The oral cavity disintegration tablet of embodiment 7 present compositions
Preparation: the technique that adopts conventional preparation oral cavity disintegration tablet, get 1.5 parts of Radix Paeoniaes, 1.2 parts of the Rhizoma Anemarrhenaes, 0.9 part in Rhizoma Curcumae Longae, 0.5 part of Herba Hyperici perforati, 1 part of Radix Bupleuri, 1 part of Folium Perillae, 0.4 part of Fructus Piperis Longi, adding 50% soak with ethanol extracted 2 times after 0.5 hour, amount of water is respectively 6 times, 4 times, extracts 2 hours for the first time, extracts 1 hour for the second time, filter, merging filtrate, concentrated, dry, add right amount of auxiliary materials after pulverizing, make the oral cavity disintegration tablet of this pharmaceutical composition.
The dispersible tablet of embodiment 8 present compositions
Preparation: the technique that adopts conventional preparation dispersible tablet, get 0.9 part of Radix Paeoniae, 1 part of the Rhizoma Anemarrhenae, 0.7 part in Rhizoma Curcumae Longae, 0.3 part of Herba Hyperici perforati, 0.6 part of Radix Bupleuri, 0.6 part of Folium Perillae, 0.6 part of Fructus Piperis Longi, adding 70% soak with ethanol extracted 2 times after 0.5 hour, amount of water is respectively 6 times, 4 times, extracts 2 hours for the first time, extracts 1 hour for the second time, filter, merging filtrate, concentrated, dry, add right amount of auxiliary materials after pulverizing, make the dispersible tablet of this pharmaceutical composition.
The test of pesticide effectiveness of embodiment 9 present compositions
The purpose of this test is to observe the present composition to the therapeutical effect of depression model mice.Present composition A, B, C all adopt extractum, and the time spent is prepared desired concn with pure water, the favourable Xueping injection of other reagent chemicalses, and 1mg/ml, people pharmaceutical Co. Ltd of Guangdong nation produces.Fluoxetine, specification 20mg/ sheet, Lilly S.A produces.
Compositions A: get 3 parts of Radix Paeoniaes, 1.2 parts in Rhizoma Curcumae Longae, 0.9 part of Herba Hyperici perforati, 1.8 parts of Radix Bupleuri, 1.8 parts of Folium Perillaes, soak after 0.5 hour and extract 2 times, amount of water is respectively 10 times, 8 times, extracted 2 hours for the first time, extracted 1 hour for the second time, filter, merging filtrate, concentrated, drying gets compositions A dry extract after the pulverizing.
Compositions B: get 2.4 parts of 3 parts of Radix Paeoniaes, 1.2 parts in Rhizoma Curcumae Longae, 0.9 part of Herba Hyperici perforati, 1.8 parts of Radix Bupleuri, 1.8 parts of Folium Perillaes, the Rhizoma Anemarrhenae and add 50% soak with ethanol and extract 2 times after 0.5 hour, add 50% amount of alcohol and be respectively 8 times, 6 times, extracted 2 hours for the first time, extracted 1 hour for the second time, filter, merging filtrate, concentrated, drying gets compositions B dry extract after the pulverizing.
Compositions C: get 3 parts of Radix Paeoniaes, 1.2 parts in Rhizoma Curcumae Longae, 0.9 part of Herba Hyperici perforati, 1.8 parts of Radix Bupleuri, 1.8 parts of Folium Perillaes, 2.4 parts of the Rhizoma Anemarrhenaes, 0.3 part of Fructus Piperis Longi, adding 70% soak with ethanol extracted 2 times after 0.5 hour, add 70% amount of alcohol and be respectively 7 times, 5 times, extracted 2 hours for the first time, extracted 1 hour for the second time, filter, merging filtrate, concentrated, drying gets compositions C dry extract after the pulverizing.
Laboratory animal: male ICR mouse is provided by west, Shanghai pul-Bi Kai laboratory animal company limited.Laboratory animal production licence number: SCXK (Shanghai) 2008-0016.The laboratory animal environmental facility quality certification number: SYXK (Hunan) 2009-0001.
This test data is checked between the result organizes with the t check analysis all with the EXCEL software processes.
1, on the impact of chronic stress depression model rat
The preparation of animal grouping and model: the reference literature method, select 50 of the close rats of Open-Field method scoring, be divided at random 6 groups, i.e. the normal saline group, model group, fluoxetine group, compositions A group, compositions B group, compositions C group is except the normal saline group, each group is accepted various stimulation in 21 days altogether, comprising: 4 ℃ of ice-water bath 3min, 40 ℃ of tepidarium 5min, fasting 24h prohibits water 24h, and 45 ° of 24h of cage incline, put upside down round the clock 24h, 50V electric shock, folder tail 1min.Wherein incline 45 ° of 24h of cage, put upside down 24h, 50V electric shock, folder tail 1min 2 times weekly round the clock, all the other stimulate weekly.Homologous stimulus can not occur continuously, makes rat can not expect the generation that stimulates.Stimulation begins the ig administration after finishing in the first week, and dosage sees Table 1.
(1) on the impact of rat body weight: behind medicine, measured the body weight of animal in 1,7,14,21 day.Body weight the results are shown in Table 1 in the 21st day.
(2) behavioristics is detected: adopt the open-field method to carry out behavioristics after modeling finishes and observe.Pass through the bottom surface block number as the horizontal anomalous movement score take animal, take upright (two fore paws are simultaneously liftoff) number of times as vertical activity score, behind medicine 21 days, every rat was only measured once, minute 3min.The results are shown in Table 1.
(3) impact that sucrose solution is consumed: measured the sucrose solution consumption on the 22nd day, when carrying out the sucrose solution consumption test, the single cage of all animals is raised and fasting, and every animal adds 1% sucrose solution 130ml, calculates the amount that animal 24h drinks 1% sucrose solution.The results are shown in Table 1.
Table 1 present composition on rat behavior learn, the impact of sucrose solution consumption and body weight (
N=10)
Annotate: compare with the blank group:
*P＜0.05,
*P＜0.01; Compare with model group:
#P＜0.05,
##P＜0.01.
As known from Table 1, with model group relatively, horizontal movement score, the score that moves both vertically, sucrose solution consumption and the body weight gain amount of fluoxetine group and present composition A, B, C group all be significantly increased (P＜0.05 or P＜0.01).Prompting, the present composition can obviously improve mobility, exploring ability and the interest of chronic stress depression model rat.
2, the impact of acquired desperate model mice
1) on the impact of outstanding tail dead time of acquired desperate model mice
Get 75 of ♂ ICR mices, SPF level, body weight 18-22g, be divided at random 5 groups, 15 every group: i.e. model group, prozac group, compositions A group, compositions B group, compositions C group, ig administration volume 20ml/kg, every day 1 time, each is organized mice and gives respectively relative medicine, and model group gives with the volume distilled water, successive administration 7 days.30min after the last administration is fixed in the mice inversion on the outstanding tail apparatus, and head records the dead time of rear 4min in the 6min apart from the about 10cm of desktop.Hang both sides and separate the animal sight line with plate, influence each other preventing.The results are shown in Table 2.
Table 2 present composition on the impact of mouse tail suspension dead time (
N=15, S)
Annotate: compare with model group
*P＜0.05,
*P＜0.01.
As known from Table 2, compare with model group, the outstanding tail dead time of fluoxetine treated animal reduces (P＜0.05); Compositions A, B, outstanding tail dead time of C treated animal reduce (P＜0.05).
2) on the impact of mice forced swimming dead time
Grouping is the same with administration.1h after the last administration, mice is individually put into the beaker of depth of water 10cm, water temperature (25 ± 2) ℃ forced swimming, observe 6min, keep the motionless state time (s) in the 4min behind the record, the fixed finger mice stops to struggle in water, or floating state, small limb activity is only arranged to keep head to keep afloat.The results are shown in Table 3.
Table 3 present composition on the impact of mice forced swimming dead time (
N=15, S)
Annotate: compare with model group,
#P＜0.05,
##P＜0.01.
As known from Table 3, compare with model group, fluoxetine treated animal non-swimming time shortens (P＜0.01); Compositions A, B, C treated animal non-swimming time shorten (P＜0.05).
2, on the impact of the depression model mice of reserpine induction
(1) on the depression model mice behavior of reserpine induction and the impact of body temperature
1) on the depression model mice lapsus palpebrae superioris of reserpine induction and motion can not behavior impact
Get ♂ ICR mice, SPF level, 120, body weight 18-22g is divided into 6 groups at random, 20 every group: namely blank is organized, model group, prozac group, compositions A group, compositions B group, compositions C group, ig administration volume 20ml/kg, every day 1 time, each is organized mice and gives respectively relative medicine, and blank group gives with the volume distilled water successive administration 18 days with model group.Lumbar injection reserpine 4mg/kg in the time of administration in the 15th day, 1h, 2h, 6h are put in animal the number of animals that eye alkali is closed in each group of observation on the support behind the injection reserpine, and eye alkali closed and closes the difference degree of grade between relatively each was organized with rank test.And after to reserpine 2h, 4h, 6h, place the circular in vain finger of diameter 7.5cm central animal, and observed 15 seconds, record each treated animal and still stayed in the interior number of animals of circle in 15 seconds, and carry out statistical procedures.The results are shown in Table 4.
Table 4 on the impact of the depression model mice catacleisis degree of reserpine induction (
N=20)
Annotate: compare with model group,
#P＜0.05,
##P＜0.01.
As known from Table 4, with model group relatively, after fluoxetine group, compositions A, B, the administration of C group 1,2, the 6h animal eyelid degree of closing significantly reduces (P＜0.05 or P＜0.01).Prompting, compositions A, B, C have the effect of the depression model mice catacleisis degree that reduces reserpine induction.
Table 5 on depression model mice zero paper of reserpine induction go too far rate impact (
N=20)
Annotate: compare with the blank group,
*P＜0.05,
*P＜0.01; Compare with model group
#P＜0.05,
##P＜0.01.
As known from Table 5, with the blank group relatively, the model group animal zero paper rate (2h, 4h, 6h behind the medicine) that goes too far significantly reduces (P＜0.01), shows the modeling success.With model group relatively, the fluoxetine group behind medicine 2, the 4h rate number of animals that goes too far significantly increases, through X
2Check difference has statistical significance (P＜0.01 or P＜0.05); Compositions A, B, C organize in 2h, 4h, the 6h zero paper number of animals that goes too far significantly increases (P＜0.01 or P＜0.05).Prompting, compositions A, B, C have the go too far effect of rate of depression model mice zero paper that increases reserpine induction.
Pharmacological tests shows, the present invention can significantly improve mobility, exploring ability and the interest of chronic stress depression model rat, the depression model mouse movement of antagonism reserpine induction can not reach body temperature to be reduced, and desperate animal model autonomic activities number, outstanding tail and non-swimming time that outstanding tail and forced swimming are induced increase.Show that the present invention has obvious antidepressant effect.
Claims (18)
1. herbal mixture that is used for the treatment of depression, it is characterized in that: it comprises the raw material of Chinese medicine of following weight portion proportioning: 0.8～3 part of Radix Paeoniae, 0.3～2 part in Rhizoma Curcumae Longae, 0.2～1 part of Herba Hyperici perforati, 0.5～2 part of Radix Bupleuri, 0.5～2 part of Folium Perillae.
2. herbal mixture that is used for the treatment of depression, it is characterized in that: it comprises the raw material of Chinese medicine of following weight portion proportioning: 0.8～3 part of Radix Paeoniae, 0.3～2 part in Rhizoma Curcumae Longae, 0.2～1 part of Herba Hyperici perforati, 0.5～2 part of Radix Bupleuri, 0.5～2 part of Folium Perillae, 0～3 part of the Rhizoma Anemarrhenae.
3. herbal mixture that is used for the treatment of depression, it is characterized in that: it comprises the raw material of Chinese medicine of following weight portion proportioning: 0.8～3 part of Radix Paeoniae, 0.3～2 part in Rhizoma Curcumae Longae, 0.2～1 part of Herba Hyperici perforati, 0.5～2 part of Radix Bupleuri, 0.5～2 part of Folium Perillae, 0～3 part of the Rhizoma Anemarrhenae, 0～1 part of Fructus Piperis Longi.
4. each described herbal mixture that is used for the treatment of depression is characterized in that being made by the raw material of Chinese medicine of following weight portion proportioning: 0.8～3 part of Radix Paeoniae, 0.3～2 part in Rhizoma Curcumae Longae, 0.2～1 part of Herba Hyperici perforati, 0.5～2 part of Radix Bupleuri, 0.5～2 part of Folium Perillae according to claim 1-3.
5. each described herbal mixture that is used for the treatment of depression is characterized in that being made by the raw material of Chinese medicine of following weight portion proportioning: 0.8～3 part of Radix Paeoniae, 0.3～2 part in Rhizoma Curcumae Longae, 0.2～1 part of Herba Hyperici perforati, 0.5～2 part of Radix Bupleuri, 0.5～2 part of Folium Perillae, 0～3 part of the Rhizoma Anemarrhenae according to claim 1-3.
6. each described herbal mixture that is used for the treatment of depression is characterized in that being made by the raw material of Chinese medicine of following weight portion proportioning: 0.8～3 part of Radix Paeoniae, 0.3～2 part in Rhizoma Curcumae Longae, 0.2～1 part of Herba Hyperici perforati, 0.5～2 part of Radix Bupleuri, 0.5～2 part of Folium Perillae, 0～3 part of the Rhizoma Anemarrhenae, 0.1～1 part of Fructus Piperis Longi according to claim 1-3.
7. each described herbal mixture that is used for the treatment of depression is characterized in that being made by the raw material of Chinese medicine of following weight portion proportioning: 3 parts of Radix Paeoniaes, 1.2 parts in Rhizoma Curcumae Longae, 0.9 part of Herba Hyperici perforati, 1.8 parts of Radix Bupleuri, 1.8 parts of Folium Perillaes according to claim 1-3.
8. each described herbal mixture that is used for the treatment of depression is characterized in that being made by the raw material of Chinese medicine of following weight portion proportioning: 3 parts of Radix Paeoniaes, 1.2 parts in Rhizoma Curcumae Longae, 0.9 part of Herba Hyperici perforati, 1.8 parts of Radix Bupleuri, 1.8 parts of Folium Perillaes, 2.4 parts of the Rhizoma Anemarrhenaes according to claim 1-3.
9. each described herbal mixture that is used for the treatment of depression is characterized in that being made by the raw material of Chinese medicine of following weight portion proportioning: 3 parts of Radix Paeoniaes, 1.2 parts in Rhizoma Curcumae Longae, 0.9 part of Herba Hyperici perforati, 1.8 parts of Radix Bupleuri, 1.8 parts of Folium Perillaes, 2.4 parts of the Rhizoma Anemarrhenaes, 0.3 part of Fructus Piperis Longi according to claim 1-3.
10. each described herbal mixture that is used for the treatment of depression according to claim 1-3 is characterized in that said composition makes clinically acceptable peroral dosage form.
11. each described herbal mixture that is used for the treatment of depression according to claim 1-3 is characterized in that said composition makes tablet, capsule, granule, pill, oral liquid.
12. each described herbal mixture that is used for the treatment of depression according to claim 1-3 is characterized in that said composition makes soft capsule, dispersible tablet, oral cavity disintegration tablet, drop pill.
13. each described herbal mixture that is used for the treatment of depression is characterized in that and will add 0～70% ethanol in the crude drug according to claim 1-3, extracts 2～3 times, adds 4～12 times of amount solvents at every turn; The each extraction 1～2 hour, extracting solution filters, and reclaims solvent and concentrated preparation.
14. each described preparation method that is used for the treatment of the herbal mixture of depression is characterized in that: will add 0～70% ethanol in the crude drug, extract 2～3 times, add 4～12 times of amount solvents according to claim 1-3 at every turn; The each extraction 1～2 hour, extracting solution filters, and reclaims solvent and concentrated preparation.
15. preparation method according to claim 14 is characterized in that adding 0～70% ethanol, extracts 2 times, adds 4～10 times of amount solvents at every turn; The each extraction 1～2 hour, extracting solution filters, and reclaims solvent and concentrated preparation.
16. preparation method according to claim 14 is characterized in that adding 0～70% ethanol, extracts 2 times, adds the solvent that 6-10 doubly measures for the first time, extracts 2 hours, adds the solvent that 4-8 doubly measures for the second time, extracts 1 hour; Extracting solution filters, and reclaims solvent and concentrated preparation.
17. each described preparation method according to claim 15-16, it is characterized in that adding 0% ethanol is water extraction.
18. according to claim 1-3 application of each described herbal mixture in the medicine of preparation Cure of depression.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210126887.XA CN103372174B (en) | 2012-04-27 | 2012-04-27 | A kind of herbal mixture that is used for the treatment of depression |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210126887.XA CN103372174B (en) | 2012-04-27 | 2012-04-27 | A kind of herbal mixture that is used for the treatment of depression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103372174A true CN103372174A (en) | 2013-10-30 |
| CN103372174B CN103372174B (en) | 2016-05-18 |
Family
ID=49458418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210126887.XA Active CN103372174B (en) | 2012-04-27 | 2012-04-27 | A kind of herbal mixture that is used for the treatment of depression |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103372174B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104435582A (en) * | 2014-12-03 | 2015-03-25 | 郝贵峰 | Traditional Chinese medicine plaster for treating depression and insomnia of middle-aged and old people |
| CN108079249A (en) * | 2017-12-28 | 2018-05-29 | 晨光生物科技集团邯郸有限公司 | A kind of Chinese medicine preparation with liver protection and preparation method thereof |
| CN114392260A (en) * | 2022-02-15 | 2022-04-26 | 重庆市九龙坡区精神卫生中心(重庆市九龙坡区石坪桥医院) | Medicine for relieving anxiety and depression |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101816766A (en) * | 2010-01-27 | 2010-09-01 | 蔡光先 | Chinese medicinal composition for treating tristimania |
-
2012
- 2012-04-27 CN CN201210126887.XA patent/CN103372174B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101816766A (en) * | 2010-01-27 | 2010-09-01 | 蔡光先 | Chinese medicinal composition for treating tristimania |
Non-Patent Citations (2)
| Title |
|---|
| 周王谊等: "抗抑郁单味中药研究进展", 《医学综述》 * |
| 毕赢等: "荜茇化学成分及药理活性研究进展", 《中国药学杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104435582A (en) * | 2014-12-03 | 2015-03-25 | 郝贵峰 | Traditional Chinese medicine plaster for treating depression and insomnia of middle-aged and old people |
| CN108079249A (en) * | 2017-12-28 | 2018-05-29 | 晨光生物科技集团邯郸有限公司 | A kind of Chinese medicine preparation with liver protection and preparation method thereof |
| CN114392260A (en) * | 2022-02-15 | 2022-04-26 | 重庆市九龙坡区精神卫生中心(重庆市九龙坡区石坪桥医院) | Medicine for relieving anxiety and depression |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103372174B (en) | 2016-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101766801B (en) | Anti-depression Xiaoyao powder effective component and extraction method thereof | |
| CN101816766B (en) | Chinese medicinal composition for treating tristimania | |
| CN102014931B (en) | Use and preparation of paeoniflorin and the composition thereof | |
| CN100522212C (en) | Traditional Chinese medicine composition for treating depression and its preparing method | |
| CN102885977B (en) | Composition with memory improving function | |
| CN106581335A (en) | Medicine composition for treating Alzheimer's disease and preparing method and application thereof | |
| CN102462825B (en) | Compound traditional Chinese medicine for treating depression | |
| CN101288761B (en) | Chinese tmedicine preparation for treating depression and its preparation method | |
| CN103372174A (en) | Compound traditional Chinese medicine for treating depression | |
| CN102258742B (en) | Chinese medicinal medicine composition for treating depression and preparation method thereof | |
| CN102579554A (en) | Peanut stem and leaf extract and preparation method as well as application thereof | |
| CN101002836B (en) | Use of the extractive of radix cynanchi bungei total glucoside | |
| CN102178721B (en) | Application of fiveleaf gynostemma herb suspension and extract to preparation of drug for treating and resisting depression | |
| CN100356940C (en) | Method for preparing piper laetispicum extract, extract and its use | |
| CN102579530A (en) | Preparation method of aralia taibaiensis total saponin having diabetes mellitus resisting effect and medicament | |
| CN104804056A (en) | Sarcopyramis nepalensis extract and application thereof | |
| CN102188477B (en) | Preparation method and application of active component of radix gentianae extractive | |
| CN105287711A (en) | Medicinal composition for treating dyspepsia | |
| CN103768454B (en) | A kind of composition with prevention and treatment HIV/AIDS and preparation method thereof | |
| CN100546637C (en) | A kind of Chinese medicine composition for the treatment of coronary heart disease and preparation method thereof | |
| CN1977888B (en) | Medicinal composition of baicalin, ganoderma lucidum and salvia miltrorrhiza | |
| CN101077407B (en) | Medicine for treating depression caused by simple emotion factor | |
| CN101390971A (en) | Use of capejasmine effective part in treating anti-depression anxiety | |
| CN103054921A (en) | Effective component extracted from bupleurum Chinese and application of antidepression activity thereof | |
| CN108186821A (en) | A kind of Chinese medicine composition for treating nervous headache and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230113 Address after: No. 300, bachelor Road, Hanpu science and Education Industrial Park, Yuelu District, Changsha City, Hunan Province, 410000 Patentee after: Hunan University of Chinese Medicine Address before: The First Affiliated Hospital of Hunan University of traditional Chinese medicine, 95 Shaoshan Middle Road, Changsha, Hunan 41007 Patentee before: Wang Yuhong Patentee before: Han Yuanshan |
|
| TR01 | Transfer of patent right |